Close Menu

NEW YORK ─ Chembio Diagnostics believes the development of new tests for SARS-CoV-2 and launch of an assay for HIV-syphilis coinfection will help put the company back on track following the revocation of an Emergency Use Authorization by the US Food and Drug Administration of its serology test for the coronavirus in June.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.